| Long name: |
NFKB p65(Ser536) Primary Polyclonal Antibody |
| Also known as: |
NFKB p65(Ser536) PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
NFKB p65 Ser536 |
| Specificity: |
This is a highly specific antibody against NFKB p65 Ser536 |
| Modification(s): |
Phosphorylation |
| Modification site(s): |
Ser536 |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
515-551/551 |
| Subcellular location: |
Nucleus, Cytoplasm |
| Source: |
KLH conjugated synthetic phosphopeptide derived from human NFKBp65 around the phosphorylation site of(Ser536) |
| Gene ID number: |
5970 |
| Swiss Prot: |
Q04206 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Associates with chromatin at the NF-kappa-B promoter region via association with DDX1, Different dimer combinations act as transcriptional activators or repressors, Essential for cytokine gene expression in T-cells (PubMed:15790681), I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, In a conventional activation pathway, NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family, NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators, NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one, RELB, The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression, The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity, The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65, cell growth, differentiation, immunity, p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex, respectively, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus, tumorigenesis and apoptosis, NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
NFKB3, Nuclear factor NF-kappa-B p65 subunit, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELA, Transcription factor p65, p65 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
NFKB p65(Ser536) |
| Short name: |
NFKB p65(Ser536) Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
NFKB p65(Ser536) (Antibody to) |
| Alternative technique: |
antibodies |